56 related articles for article (PubMed ID: 27381831)
1. Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients.
Sclafani F; Chau I; Cunningham D; Lampis A; Hahne JC; Ghidini M; Lote H; Zito D; Tabernero J; Glimelius B; Cervantes A; Begum R; De Castro DG; Wilson SH; Peckitt C; Eltahir Z; Wotherspoon A; Tait D; Brown G; Oates J; Braconi C; Valeri N
Carcinogenesis; 2016 Sep; 37(9):852-7. PubMed ID: 27381831
[TBL] [Abstract][Full Text] [Related]
2. A common variant in MTHFR influences response to chemoradiotherapy and recurrence of rectal cancer.
Nikas JB; Lee JT; Maring ED; Washechek-Aletto J; Felmlee-Devine D; Johnson RA; Smyrk TC; Tawadros PS; Boardman LA; Steer CJ
Am J Cancer Res; 2015; 5(10):3231-40. PubMed ID: 26693073
[TBL] [Abstract][Full Text] [Related]
3. Serum miR-143 levels predict the pathological response to neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer.
Hiyoshi Y; Akiyoshi T; Inoue R; Murofushi K; Yamamoto N; Fukunaga Y; Ueno M; Baba H; Mori S; Yamaguchi T
Oncotarget; 2017 Oct; 8(45):79201-79211. PubMed ID: 29108299
[TBL] [Abstract][Full Text] [Related]
4. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.
Bahadoer RR; Dijkstra EA; van Etten B; Marijnen CAM; Putter H; Kranenbarg EM; Roodvoets AGH; Nagtegaal ID; Beets-Tan RGH; Blomqvist LK; Fokstuen T; Ten Tije AJ; Capdevila J; Hendriks MP; Edhemovic I; Cervantes A; Nilsson PJ; Glimelius B; van de Velde CJH; Hospers GAP;
Lancet Oncol; 2021 Jan; 22(1):29-42. PubMed ID: 33301740
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in MRI-Defined Locally Advanced T3 Resectable Rectal Cancer: Final Results of a Randomized, Noncomparative Phase 2 INOVA Study.
Borg C; Mantion G; Boudghène F; Mornex F; Ghiringhelli F; Adenis A; Azria D; Balosso J; Ben Abdelghani M; Bachet JB; Vendrely V; François Y; Conroy T; Rio E; Roullet B; Spaëth D; Quero L; Lakkis Z; Coudert M; Ionescu-Goga M; Tanang A; André T
Clin Colorectal Cancer; 2019 Sep; 18(3):200-208.e1. PubMed ID: 31311761
[TBL] [Abstract][Full Text] [Related]
6. Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer.
Miyo M; Kato T; Yoshino T; Yamanaka T; Bando H; Satake H; Yamazaki K; Taniguchi H; Oki E; Kotaka M; Oba K; Miyata Y; Muro K; Komatsu Y; Baba H; Tsuji A
BMC Cancer; 2020 Jul; 20(1):687. PubMed ID: 32703200
[TBL] [Abstract][Full Text] [Related]
7. Long-course neoadjuvant chemoradiotherapy with versus without a concomitant boost in locally advanced rectal cancer: a randomized, multicenter, phase II trial (FDRT-002).
Wang J; Guan Y; Gu W; Yan S; Zhou J; Huang D; Tong T; Li C; Cai S; Zhang Z; Zhu J
Radiat Oncol; 2019 Nov; 14(1):215. PubMed ID: 31783766
[TBL] [Abstract][Full Text] [Related]
8. ACRNaCT trial protocol: efficacy of adjuvant chemotherapy in patients with clinical T3b/T4, N+ rectal Cancer undergoing Neoadjuvant Chemoradiotherapy: a pathology-oriented, prospective, multicenter, randomized, open-label, parallel group clinical trial.
Li Q; Luo D; Zhu J; Yang L; Liu Q; Ma Y; Liang L; Cai S; Zhang Z; Li X;
BMC Cancer; 2019 Nov; 19(1):1117. PubMed ID: 31729964
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant Radiotherapy with Capecitabine Plus Bevacizumab for Locally Advanced Lower Rectal Cancer: Results of a Single-institute Phase II Study.
Maeda K; Shibutani M; Otani H; Fukuoka T; Iseki Y; Matsutani S; Nagahara H; Inoue T; Tachimori A; Nishii T; Miki Y; Hosono M; Ohira M
Anticancer Res; 2018 Jul; 38(7):4193-4197. PubMed ID: 29970549
[TBL] [Abstract][Full Text] [Related]
10. Impact of age on the efficacy of oxaliplatin in the preoperative chemoradiotherapy and adjuvant chemotherapy of rectal cancer: a post hoc analysis of the CAO/ARO/AIO-04 phase III trial.
Hofheinz RD; Arnold D; Fokas E; Kaufmann M; Hothorn T; Folprecht G; Fietkau R; Hohenberger W; Ghadimi M; Liersch T; Grabenbauer GG; Sauer R; Rödel C; Graeven U;
Ann Oncol; 2018 Aug; 29(8):1793-1799. PubMed ID: 29873684
[TBL] [Abstract][Full Text] [Related]
11. KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer.
Sclafani F; Chau I; Cunningham D; Hahne JC; Vlachogiannis G; Eltahir Z; Lampis A; Braconi C; Kalaitzaki E; De Castro DG; Wotherspoon A; Capdevila J; Glimelius B; Tarazona N; Begum R; Lote H; Hulkki Wilson S; Mentrasti G; Brown G; Tait D; Oates J; Valeri N
Sci Rep; 2018 Jan; 8(1):1445. PubMed ID: 29362371
[TBL] [Abstract][Full Text] [Related]
12. Modified FOLFOX6 With or Without Radiation Versus Fluorouracil and Leucovorin With Radiation in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: Initial Results of the Chinese FOWARC Multicenter, Open-Label, Randomized Three-Arm Phase III Trial.
Deng Y; Chi P; Lan P; Wang L; Chen W; Cui L; Chen D; Cao J; Wei H; Peng X; Huang Z; Cai G; Zhao R; Huang Z; Xu L; Zhou H; Wei Y; Zhang H; Zheng J; Huang Y; Zhou Z; Cai Y; Kang L; Huang M; Peng J; Ren D; Wang J
J Clin Oncol; 2016 Sep; 34(27):3300-7. PubMed ID: 27480145
[TBL] [Abstract][Full Text] [Related]
13. Biological Functions and Molecular Mechanisms of MiR-608 in Cancer.
Lu J; Zhu D; Li L
Front Oncol; 2022; 12():870983. PubMed ID: 35387124
[TBL] [Abstract][Full Text] [Related]
14. Is there an efficacy-effectiveness gap between randomized controlled trials and real-world studies in colorectal cancer: a systematic review and meta-analysis.
Zhang X; Fu S; Meng R; Ren Y; Shang Y; Tian L
Transl Cancer Res; 2020 Nov; 9(11):6963-6987. PubMed ID: 35117304
[TBL] [Abstract][Full Text] [Related]
15. Single Nucleotide Polymorphisms in microRNA Genes and Colorectal Cancer Risk and Prognosis.
Radanova M; Levkova M; Mihaylova G; Manev R; Maneva M; Hadgiev R; Conev N; Donev I
Biomedicines; 2022 Jan; 10(1):. PubMed ID: 35052835
[TBL] [Abstract][Full Text] [Related]
16. The Role of Micro-RNAs and Circulating Tumor Markers as Predictors of Response to Neoadjuvant Therapy in Locally Advanced Rectal Cancer.
De Palma FDE; Luglio G; Tropeano FP; Pagano G; D'Armiento M; Kroemer G; Maiuri MC; De Palma GD
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32987896
[TBL] [Abstract][Full Text] [Related]
17. Germline and Somatic Pharmacogenomics to Refine Rectal Cancer Patients Selection for Neo-Adjuvant Chemoradiotherapy.
De Mattia E; Roncato R; Palazzari E; Toffoli G; Cecchin E
Front Pharmacol; 2020; 11():897. PubMed ID: 32625092
[TBL] [Abstract][Full Text] [Related]
18. MicroRNAs (miRNAs) and Long Non-Coding RNAs (lncRNAs) as New Tools for Cancer Therapy: First Steps from Bench to Bedside.
Ratti M; Lampis A; Ghidini M; Salati M; Mirchev MB; Valeri N; Hahne JC
Target Oncol; 2020 Jun; 15(3):261-278. PubMed ID: 32451752
[TBL] [Abstract][Full Text] [Related]
19. Non-Coding RNAs and Resistance to Anticancer Drugs in Gastrointestinal Tumors.
Hahne JC; Valeri N
Front Oncol; 2018; 8():226. PubMed ID: 29967761
[TBL] [Abstract][Full Text] [Related]
20. The SNPs in pre-miRNA are related to the response of capecitabine-based therapy in advanced colon cancer patients.
Mao Y; Zou C; Meng F; Kong J; Wang W; Hua D
Oncotarget; 2018 Jan; 9(6):6793-6799. PubMed ID: 29467929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
